KRAS and colorectal carcinoma: As shown in Figure 2B,C, KRAS-mutated SW1463 (G12C) cells showed higher resistance to cetuximab in comparison to other KRAS-mutant CRC cells both dose/time-dependent, whereas maximum inhibition in cell proliferation of the KRAS-wild type Caco-2 cells was achieved at the given concentration of cetuximab.